0001209191-19-014993.txt : 20190301
0001209191-19-014993.hdr.sgml : 20190301
20190301163112
ACCESSION NUMBER: 0001209191-19-014993
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20190227
FILED AS OF DATE: 20190301
DATE AS OF CHANGE: 20190301
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Danziger Asaf
CENTRAL INDEX KEY: 0001654435
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37565
FILM NUMBER: 19649872
MAIL ADDRESS:
STREET 1: 5 NACHUM CHAT ST.
CITY: TIRAT HACARMEL
STATE: L3
ZIP: 5112302
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: NovoCure Ltd
CENTRAL INDEX KEY: 0001645113
STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
IRS NUMBER: 000000000
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: NO. 4 THE FORUM
STREET 2: GRENVILLE STREET
CITY: ST. HELIER
STATE: Y9
ZIP: JE2 4UF
BUSINESS PHONE: 44 (0)15 3475 6700
MAIL ADDRESS:
STREET 1: NO. 4 THE FORUM
STREET 2: GRENVILLE STREET
CITY: ST. HELIER
STATE: Y9
ZIP: JE2 4UF
FORMER COMPANY:
FORMER CONFORMED NAME: Novocure Ltd
DATE OF NAME CHANGE: 20150615
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2019-02-27
0
0001645113
NovoCure Ltd
NVCR
0001654435
Danziger Asaf
C/O NOVOCURE INC.
20 VALLEY STREAM PARKWAY, SUITE 300
MALVERN
PA
19355
1
1
0
0
Chief Executive Officer
Ordinary Shares
2019-02-27
4
M
0
9260
52.90
A
233757
D
Ordinary Shares
2019-02-28
4
M
0
903
14.37
A
234660
D
Ordinary Shares
2019-02-28
4
S
0
903
54.395
D
233757
D
Restricted Stock Units
0.00
2019-02-27
4
M
0
9260
0.00
D
2019-02-27
Ordinary Shares
9260
18518
D
Options to Buy Ordinary Shares
14.37
2019-02-28
4
M
0
903
0.00
D
2025-02-23
Ordinary Shares
903
353887
D
These shares were sold pursuant to a Rule 10b5-1 trading plan adopted by Mr. Danziger.
On February 28, 2019, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Danziger, Mr. Danziger sold 903 shares in multiple trades at prices ranging from $54.37 to $54.44. The price reported above reflects the weighted average sale price. Mr. Danziger hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected.
Fully vested as of the date hereof.
Fully vested and currently exercisable as of the date hereof.
By: /s/ Kimberly Burke, Attorney in fact for Asaf Danziger
2019-03-01